Dr. Ira Kurtz Joins Implantable Artificial Kidney Corp Advisory Board

LOS ANGELES - Oct. 14, 2014 - PRLog -- After a lengthy search,  Dr. Ira Kurtz, Chief of the University of California, Los Angeles (UCLA) Division of Nephrology was invited to join the Advisory Board of the Implantable Artificial Kidney Corporation (IAKC).  Dr. Kurtz will play an important role in advising IAKC in all aspects of the research and development of the IAK-1 implantable artificial kidney.  Dr. Kurtz will assist IAKC to advance the development of the IAK-1 through all phases of laboratory and animal testing, and ultimately human trials, leading to approval of the IAK-1 by the FDA.

“Dr. Ira Kurtz brings years of experience, insight and knowledge to our project. He is a dedicated kidney doctor, research scientist, and professor with vast knowledge of the function of the human kidney.  His background will prove instrumental in the further development of the IAK-1. We are very fortunate to have him involved”, said Roland G. Ludlow, IAKC’s CEO/President.

About Dr. Ira Kurtz, M.D., FRCP (C)

Professor of Medicine, Chief of the Division of Nephrology at UCLA, Factor Chair in Molecular Nephrology

Dr. Kurtz is a board certified internist and nephrologist who has been practicing clinical nephrology for nearly 30 years. He is a graduate of the University of Toronto, and completed his postgraduate training at the University of California, San Francisco, and the National Institute of Health. Dr. Kurtz is a member of the American Society of Clinical Investigation, the American Physiological Society, the Biophysical Society, the American Society of Nephrology, and is a Fellow of the Royal College of Physicians and Surgeons of Canada. On faculty at UCLA since 1985, Dr. Kurtz has authored over 300 scientific publications, book chapters, and abstracts. He is on the editorial board of several journals and is a reviewer of major scientific publications.

About Implantable Artificial Kidney Corp (IAKC): TX - CA

IAKC is solely involved in the research and development of a fully functional implantable artificial kidney.  The company currently possess a patented prototype that is being further developed and tested.